Subclinical hyperthyroidism: Clinical features and treatment options

European Journal of Endocrinology

Volumn 152, Issue 1, 2005, Pages 1-9

  Biondi, Bernadette ^a   Palmieri, Antonio ^a   Klain, Michele ^a   Schlumberger, Martin ^b   Filetti, Sebastiano ^c   Lombardi, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ESTROGEN; IODINATED CONTRAST MEDIUM; IODINE; LEVOTHYROXINE; RADIOACTIVE IODINE; THIAMAZOLE; THYROID HORMONE; THYROTROPIN;

ADRENERGIC ACTIVITY; BONE INJURY; CALCIUM INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CLINICAL FEATURE; CLINICAL TRIAL; DIASTOLE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG DOSE REGIMEN; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; EXERCISE TOLERANCE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HEART PERFORMANCE; HEART RATE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HORMONAL THERAPY; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MORBIDITY; MORTALITY; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; POSTMENOPAUSE; PRIORITY JOURNAL; PSYCHOSOMATICS; QUALITY OF LIFE; REVIEW; SECONDARY PREVENTION; SYMPTOMATOLOGY; SYSTOLE; THYROID CANCER; THYROID NODULE; TUMOR DIFFERENTIATION; WELLBEING;

ADRENERGIC BETA-ANTAGONISTS; AGED; BISOPROLOL; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYPERTHYROIDISM; OSTEOPOROSIS; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

EID: 13244257200     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.01809     Document Type: Review

References (115)

1. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Burman KD, Denke MA, Cooper RS & Weissman NJ. Subclinical thyroid disease. Scientific review and guidelines for diagnosis and management. Journal of the American Medical Association 2004 291 228-238.
2. McDermott MT, Woodmansee WW, Haugen BR, Smart A & Ridgway EC. The management of subclinical hyperthyroidism by thyroid specialists. Thyroid 2003 13 1133-1139.
3. Ladenson PW. Thyrotoxicosis and the heart: something old and something new. Journal of Clinical Endocrinology and Metabolism 1993 77 332-333.
4. Andersen S, Pedersen KM, Brunn NH & Laurberg P. Narrow individual variations in serum T4 and T3 in normal subjects: a clue to understanding of subclinical thyroid disease. Journal of Clinical Endocrinology and Metabolism 2002 87 1068-1072.
5. Carr D, McLeod DT Parry G & Thornes HM. Fine adjustment of thyroxine replacement dosage: comparison of the thyrotropin releasing hormone test using sensitive thyrotropin assay with measurement of free thyroid hormone and clinical assessment. Clinical Endocrinology 1988 28 325-333.
6. Spencer CA, Lopresti JS, Patel A, Guttler RB, Eigen A, Shen D, Gray D & Nicoloff JT. Applications of a new chemiluminescent thyrotropin assay to subnormal measurement. Journal of Clinical Endocrinology and Metabolism 1990 70 453-460.
7. Meier CA, Maisen MN, Lowry A, Müller J & Smith MA. Interindividual differences in the pituitary-thyroid axis influence the interpretation of thyroid function tests. Clinical Endocrinology 1993 39 101-107.
8. Ross DS. Subclinical thyrotoxicosis. In Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text, pp 1016-1020, edn 8. Eds LE Braverman & RD Utiger. Philadelphia: Lippincott Williams and Wilkins, 2000.
9. de Whalley P. Do abnormal thyroid stimulating hormone level values result in treatment changes? A study of patients on thyroxine in one general practice. British Journal of General Practice 1995 45 93-95.
10. Canaris GJ, Manovitz NR, Mayor G & Ridgway EC. The Colorado thyroid disease prevalence study. Archives of Internal Medicine 2000 160 526-534.
11. Belfiore A, Sava L, Runello F, Tomaselli L & Vigneri R. Solitary autonomously functioning thyroid nodules and iodine deficiency. Journal of Clinical Endocrinology and Metabolism 1996 56 283-287.
12. Stott DJ, McLellan AR, Finlayson J, Chu P & Alexander WD. Elderly patients with suppressed serum TSH but normal free thyroid hormone levels usually have mild thyroid overactivity and are at risk of developing overt hyperthyroidism. Quarterly Journal of Medicine 1991 78 77-84.
13. Aghini-Lombardi F, Antonangeli L, Martino E, Vitti P, Maccherini D, Leoli F, Rago T, Grasso L, Valeriano R, Balestrieri A & Pinchera A. The spectrum of thyroid disease in an iodine-deficient community: the Pescopagano survey. Journal of Clinical Endocrinology and Metabolism 1999 84 561-566.
14. Spencer C, Eigen A, Shen D, Duda M, Qualls S, Weiss S & Nicoloff J. Specificity of sensitive assay of thyrotropin (TSH) used to screen for thyroid disease in hospitalized patients. Clinical Chemistry 1987 33 1391-1396.
15. Drinka PJ. Abnormal TSH: a rational approach to the older patient. Geriatrics 1999 54 58-65.
16. Marqusee E, Haden ST & Utiger RD. Subclinical thyrotoxicosis. Endocrinology and Metabolism Clinics of North America 1998 27 37-49.
17. Wang C & Crapo LM. The epidemiology of thyroid diseases and implications for screening. Endocrinology and Metabolism Clinics of North America 1977 26 189-218.
18. Samuels MH. Subclinical thyroid disease in the elderly. Thyroid 1998 8 803-813.
19. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA & Braverman LE. Serum TSH T(4), and thyroid antibodies in the United States population (1988-1994): National Health and Nutrition Examination Survey (NHANESIII). Journal of Clinical Endocrinology and Metabolism 2002 87 486-488.
20. Wiersinga WM. Subclinical hyperthyroidism and hypothyroidism. Prevalence and clinical relevance. Netherlands Journal of Medicine 1995 46 197-204.
21. Parle JV, Franklyn JA, Cross KW, Jones SC & Sheppard MC. Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. Clinical Endocrinology 1991 34 77-83.
22. Schlote B, Schaaf L, Schmidt R, Pohl T, Vardarli I, Schiebeler H, Zober MA & Usadel KH. Mental and physical state in subclinical hyperthyroidism: investigations in a normal working population. Biological Psychiatry 1992 32 48-56.
23. Biondi B, Fazio S, Carella C, Sabatini D, Amato G, Cittadini A, Bellastella A, Lombardi G & Sacca L. Control of adrenergic over-activity by β-blockade improves quality of life in patients receiving long term suppressive therapy with levothyroxine. Journal of Clinical Endocrinology and Metabolism 1994 78 1028-1033.
24. Shapiro LE, Sievert R, Ong L, Ocampo EL, Chance RA, Lee M, Nanna M, Ferrick K & Surks MI. Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of L-thyroxine. Journal of Clinical Endocrinology and Metabolism 1997 82 2592-2595.
25. Mercuro G, Panzuto MG, Bina A, Leo M, Cabura R, Petrini L, Pigliaru F & Mariotti S. Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring. Journal of Clinical Endocrinology and Metabolism 2000 85 159-164.
26. Biondi B, Palmieri EA, Fazio S, Cosco C, Nocera M, Saccà L, Filetti S, Lombardi G & Perticone F. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. Journal of Clinical Endocrinology and Metabolism 2000 85 4701-4705.
27. Sgarbi JA, Villaca F, Garbeline B, Villar HE & Romaldini JH. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism on clinical and heart abnormalities. Journal of Clinical Endocrinology and Metabolism 2003 88 1672-1677.
28. Bommer M, Eversmann T, Pickardt R, Leonhardt A & Naber D. Psychopathological and neuropsychological symptoms in patients with subclinical and remitted hyperthyroidism. Klinische Wochenschrift 1990 68 552-558.
29. Kalmijn S, Mehta KM, Pols HA, Hofman A, Drexhage HA & Breteler MM. Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study. Clinical Endocrinology 2000 53 733-737.
30. Biondi B, Palmieri EA, Lombardi G & Fazio S. Effects of thyroid hormone on cardiac function: the relative importance of heart rate, loading conditions, and myocardial contractility in the regulation of cardiac performance in human hyperthyroidism. Journal of Clinical Endocrinology and Metabolism 2002 87 968-974.
31. Klein I & Ojamaa K. Thyroid hormone and the cardiovascular system. New England Journal of Medicine 2001 344 501-509.
32. Fazio S, Palmieri EA, Lombardi G & Biondi B. Effects of thyroid hormone on the cardiovascular system. Recent Progress in Hormone Research 2004 59 31-50.
33. Bell GM, Sawers SA, Forfar JC, Doig A & Toft D. The effect of minor increments in plasma thyroxine on heart rate and urinary sodium excretion. Clinical Endocrinolology 1983 18 511-516.
34. Grund FM & Niewoehner CB. Hyperthyroidism in patients receiving thyroid replacement therapy. Archives of Internal Medicine 1989 149 921-929.
35. Biondi B, Fazio S, Carella C, Amato G, Cittadini A, Lupoli G, Sacca L, Bellastella A & Lombardi G. Cardiac effects of long-term thyrotropin-suppressive therapy with levothyroxine. Journal of Clinical Endocrinology and Metabolism 1993 77 334-338.
36. Biondi B, Fazio S, Palmieri EA, Tremalaterra R, Angellotti G, Bonè F, Riccio G, Cittadini A, Lombardi G & Saccà L. Effects of chronic subclinical hyperthyroidism on cardiac morphology and function. Cardiologia 1999 44 443-449.
37. 4 and low TSH response to TRH. Clinical Endocrinology 1986 25 579-588.
38. Biondi B, Fazio S, Coltorti F, Palmieri EA, Carella C, Lombardi G & Saccà L. Clinical case seminar: Reentrant atrioventricular nodal tachycardia induced by levothyroxine. Journal of Clinical Endocrinology and Metabolism 1998 83 2643-2645.
39. Tenerz A, Forberg R & Jansson R. Is a more active attitude warranted in patients with subclinical thyrotoxicosis? Journal of Internal Medicine 1999 228 229-233.
40. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wilson PW, Benjamin EJ & D'Agostino RB. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. New England Journal of Medicine 1994 331 1249-1252.
41. Auer JA, Scheibner P, Mische T, Langsteger W, Eber O & Eber B. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. American Heart Journal 2001 142 838-842.
42. Hammer J, Johanningmann K, Schatz H & Pfeilschifter J. Subclinical hyperthyroidism is an independent risk factor for atrial fibrillation in patients with preexisting cardiac disease. Experimental and Clinical Endocrinology and Diabetes 2001 109 S37.
43. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB & Levy D. Impact of atrial fibrillation on the risk of death. Circulation 1988 98 946-952.
44. Yuan Z, Bowlin S, Einstadter D, Cebul RD, Conners AR & Rimm AA. Atrial fibrillation as a risk factor for stroke: a retrospective cohort study of hospitalized Medicare beneficiaries. American Journal of Public Health 1998 88 395-400.
45. Ching GW, Franklyn JA, Stallard TJ, Daykin J, Sheppard M & Gammage MD. Cardiac hypertrophy as a result of long-term thyroxine therapy and thyrotoxicosis. Heart 1996 75 363-368.
46. Tseng KH, Walfish PG, Persaud JA & Gilbert BW. Concurrent aortic and mitral valve echocardiography permits measurement of systolic time intervals as an index of peripheral tissue thyroid function status. Journal of Clinical Endocrinology and Metabolism 1989 69 633-638.
47. Jennings PE, O'Malley BP, Griffin KE, Northover B & Rosenthal FD. Relevance of increased serum thyroxine concentrations associated with normal triiodothyronine values in hypothyroid patients receiving thyroxine: a case for 'tissue thyrotoxicosis'. British Medical Journal 1984 289 1645-1647.
48. Banovac K, Papic M, Bisker MS, Zakarija M & McKenzie JM. Evidence of hyperthyroidism in apparently euthyroid patients treated with levothyroxine. Archives of Internal Medicine 1989 149 809-812.
49. Fazio S, Biondi B, Carella C, Sabatini D, Cittadini A, Panza N, Lombardi G & Saccà L. Diastolic dysfunction in patients on thyroid-stimulating-hormone suppressive therapy with levothyroxine: beneficial effect of β blockade. Journal of Clinical Endocrinology and Metabolism 1995 80 2222-2226.
50. Petretta M, Bonaduce D, Spinelli L, Vicario MLE, Nuzzo V, Marciano F, Camuso P, de Sanctis V & Lupoli G. Cardiovascular haemodynamics and cardiac autonomic control in patients with subclinical and overt hyperthyroidism. European Journal of Endocrinology 2001 145 691-696.
51. Klein I. Thyroxine-induced cardiac hypertrophy: time course of development and inhibition by propanolol. Endocrinology 1988 123 203-210.
52. Rohrer D & Dillman WH. Thyroid hormones markedly increase the mRNA coding for sarcoplasmic reticulum Ca2 + -ATPase in the rat heart. Journal of Biological Chemistry 1988 263 6941-6944.
53. Biondi B, Fazio S, Cuocolo A, Sabatini D, Nicolai E, Lombardi G, Salvatore M & Sacca L. Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine. Journal of Clinical Endocrinology and Metabolism 1996 81 4224-4228.
54. Parle JV, Maisonneuve P, Sheppard MC, Boyle P & Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 2001 358 861-865.
55. Biondi B, Fazio S, Palmieri EA, Filetti S, Lombardi G & Fazio S. Mortality in elderly patients with subclinical hyperthyroidism. Lancet 2002 359 799-800.
56. Toh SH, Claunch BC & Brown PH. Effect of hyperthyroidism and its treatment on bone mineral content. Archives of Internal Medicine 1985 145 883-886.
57. Rosen CJ & Adler RA. Longitudinal changes in lumbar bone density among thyrotoxic patients after attainment of euthyroidism. Journal of Clinical Endocrinology and Metabolism 1992 75 1531-1534.
58. Vestergaard P, Rejnmark L, Weeke J & Mosekilde L. Fracture risk in patients treated for hyperthyroidism. Thyroid 2000 10 341-348.
59. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J & Boyle P. Mortality after the treatment of hyperthyroidism with radioactive iodine. New England Journal of Medicine 1998 338 712-718.
60. Ongphiphadhanakul B, Alex S, Braverman LE & Baran DT. Excessive L-thyroxine therapy decreases femoral bone mineral densities in the male rat: effect of hypogonadism and calcitonin. Journal of Bone and Mineral Research 1992 7 1227-1231.
61. Ross DS, Ardisson LJ, Nussbaum SR & Meskell MJ. Serum osteocalcin in patients taking L-thyroxine who have subclinical hyperthyroidism. Journal of Clinical Endocrinology and Metabolism 1991 72 507-509.
62. Faber J, Perrild H & Johansen JS. Bone GLA protein and sex hormone binding globulin in non-toxic goiter. Parameters for metabolic status at tissue level. Journal of Clinical Endocrinology and Metabolism 1990 70 49-55.
63. Harvey RD, McHardy KC, Reid IW, Paterson F, Bewsher PD, Duncan A & Robins SP. Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replacement therapy using pyridinium cross-links as specific urinary markers. Journal of Clinical Endocrinology and Metabolism 1991 72 1189-1194.
64. Loviselli A, Mastinu R, Rizzolo E, Massa GM, Velluzzi F, Sammartano L, Mela Q & Mariotti S. Circulating telopeptide type I is a peripheral marker of thyroid hormone action in hyperthyroidism and during levothyroxine suppressive therapy. Thyroid 1997 7 561-566.
65. Kumeda Y, Inaba M, Tahara H, Kurioka Y, Ishikawa T & Mori H. Persistent increase in bone turnover in Graves's patients with subclinical hyperthyroidism. Journal of Clinical Endocrinology and Metabolism 2000 85 4157-4161.
66. Ross DS, Neer RM, Ridgway EC & Daniels GH. Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary thyroid axis with L-thyroxine. American Journal of Medicine 1987 82 1167-1170.
67. Paul TL, Kerrigan J, Kelly AM, Braverman LE & Baran DT. Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women. Journal of the American Medical Association 1988 259 3137-3141.
68. Taelman P, Kaufman JM, Janssen X, Vandecauter H & Vermeulen A. Reduced forearm bone mineral content and biochemical evidence of increased bone turnover in women with euthyroid goiter treated with thyroid hormone. Clinical Endocrinology 1990 33 107-117.
69. Diamond T, Neri L & Hales I. A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 1990 72 1184-1188.
70. Lemke J, Bogner U, Felsenber D, Peters H & Schleusener H. Determination of bone mineral density by quantitative computed tomography and single photon absorptiometry in subclinical hyperthyroidism: a risk of early osteopenia in post-menopausal women. Clinical Endocrinology 1992 36 511-517.
71. Schneider DL, Barrett-Connor EL & Morton DL. Thyroid hormone use and bone mineral density in elderly women. Effects of estrogen. Journal of the American Medical Association 1994 271 1245-1249.
72. Kung AW, Lorentz T & Tam SC. Thyroxine suppressive therapy decreases bone mineral density in post-menopausal women. Clinical Endocrinology 1993 39 535-540.
73. Muddle AH, Houben AJ & Nieuwenhuijzen Kruseman AC. Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism. Clinical Endocrinology 1994 41 421-424.
74. Foldes J, Tarjan G, Szathmary M, Varga F, Krasznai I & Horvath C. Bone mineral density in patients with endogenous subclinical hyperthyroidism: is the thyroid status a risk factor for osteoporosis? Clinical Endocrinology 1993 39 521-527.
75. Gurlek A & Gedik O. Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women. Thyroid 1999 9 534-543.
76. Gorres G, Kaim A, Otte A, Gotze M & Muller Brand J. Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated thyroid carcinoma. European Journal of Nuclear Medicine 1996 23 690-692.
77. Marcocci C, Golia F, Vignali F & Pinchera A. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine. Journal of Bone and Mineral Research 1997 12 72-77.
78. Marcocci C, Golia F, Bruno-Bossio G, Vignali E & Pinchera A. Carefully monitored levothyroxine therapy is not associated with bone loss in premenopausal women. Journal of Clinical Endocrinology and Metabolism 1994 78 818-823.
79. Florkowski CM, Brownlie BE, Elliot JR, Aylin EM & Turner JG. Bone mineral density in patients receiving suppressive doses of thyroxine for thyroid carcinoma. New Zealand Medical Journal 1993 106 443-444.
80. Muller CG, Bayley TA, Harrison JE & Tsang R. Possible limited bone loss with suppressible thyroxine therapy is to have clinical relevance. Thyroid 1995 5 81-87.
81. Franklyn JA, Betteridge J, Daykin J, Holder R, Oates GD, Parle JV, Lilley J, Heath DA & Sheppard MC. Long-term treatment and bone mineral density. Lancet 1992 340 9-13.
82. Giannini S, Nobile M, Sartori L, Binotto P, Ciuffreda M, Gemo G, Pelizzo MR, D'Angelo A & Crepaldi G. Bone density and mineral metabolism in thyroidectomized patients treated with long-term thyroxine. Clinical Science 1994 87 593-597.
83. Garton M, Reid I, Loveridge N, Robins S, Murchison L, Beckett G & Reid D. Bone mineral density and metabolism in premenopausal women taking L-thyroxine replacement therapy. Clinical Endocrinology 1994 41 747-755.
84. De Rosa G, Testa A, Maussier ML, Calla C, Astazi P & Albanese C. A slight suppressive dose of L-thyroxine does not affect bone turnover and bone mineral density in pre- and postmenopausal women with non-toxic goiter. Hormone and Metabolic Research 1995 27 503-507.
85. Nuzzo V, Lupoli G, del Puente E, Rampone E, Carpinelli A, del Puente AE & Oriente P. Bone mineral density in premenopausal women receiving levothyroxine suppressive therapy. Gynecological Endocrinology 1998 12 333-337.
86. Saggese G, Bertelloni S, Baroncelli GI, Costa S & Ceccarelli C. Bone mineral density in adolescent females treated with L-thyroxine: a longitudinal study. European Journal of Pediatrics 1996 155 452-457.
87. Adlin EV, Maurer AH, Marks AD & Channick BJ. Bone mineral density in postmenopausal women treated with L-thyroxine. American Journal of Medicine 1991 90 360-366.
88. Grant DJ, McMurdo ME, Mole PA, Paterson CR & Davies RR. Suppressed TSH secondary to thyroxine therapy are not associated with osteoporosis. Clinical Endocrinology 1993 39 529-533.
89. Ribot C, Tremollieres F, Pouilles JM & Louvet JP. Bone mineral density and thyroid hormone therapy. Clinical Endocrinology 1990 33 143-153.
90. Hawkins F, Rigopoulou D, Papapietro K & Lopez MB. Spinal bone mass after long term treatment with L-thyroxine in postmenopausal women with thyroid cancer and chronic lymphocytic thyroiditis. Calcified Tissue International 1994 54 16-19.
91. Bauer DC, Newitt MC, Ettinger B & Stone K. Low thyrotropin levels are not associated with bone loss in older women: a prospective study. Journal of Clinical Endocrinology and Metabolism 1977 82 2931-2936.
92. Pioli G, Pedrazzoni M, Palummeri E, Sianesi M, del Frate R, Vescovi PP, Prisco M, Ulietti V, Costi D & Passeri M. Longitudinal study of bone loss after thyroidectomy and suppressive thyroxine therapy in premenopausal women. Acta Endocrinologica 1992 126 238-242.
93. McDermott MT, Perloff JJ & Kidd GS. A longitudinal assessment of bone loss in women with levothyroxine-suppressed benign thyroid disease and thyroid cancer. Calcified Tissue International 1995 56 521-525.
94. Rosen HN, Moses AC, Garber J, Ross DS, Lee SL, Ferguson L, Chen V, Lee K & Greenspan SL. Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate. Journal of Clinical Endocrinology and Metabolism 1998 83 2324-2330.
95. Guo CY, Weetman AP & Eastell R. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine. Clinical Endocrinology 1997 46 301-307.
96. Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP & Perret GY. Effects on bone mass of long-term treatment with thyroid hormones: a meta-analysis. Journal of Clinical Endocrinology and Metabolism 1996 81 4278-4289.
97. Faber J & Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. European Journal of Endocrinology 1994 130 350-356.
98. Foldes J, Lakatos P, Zsadanyi J & Horvath C. Decreased serum IGF-I and dehydroepiandrosterone sulphate may be risk factors for the development of reduced bone mass in postmenopausal women with endogenous subclinical hyperthyroidism. European Journal of Endocrinology 1997 136 277-281.
99. Franklyn J, Betteridge J, Holder R, Daykin J, Lilley J & Sheppard M. Bone mineral density in thyroxine treated females with or without a previous history of thyrotoxicosis. Clinical Endocrinology 1994 41 425-432.
100. Grant DJ, McMurdo ET, Mole PA & Peterson CR. Is previous hyperthyroidism still a risk factor for ostoporosis in post-menopausal women? Clinical Endocrinology 1995 43 339-345.
101. Solomon BL, Wartofsky L & Burman KD. Prevalence of fractures in postmenopausal women with thyroid disease. Thyroid 1993 3 17-23.
102. Leese GP, Jung RT, Guthrie C, Waugh N & Browning MC. Morbidity in patients on L-thyroxine: a comparison of those with a normal TSH to those with a suppressed TSH. Clinical Endocrinology 1992 37 500-503.
103. Sheppard MC, Holder R & Franklyn JA. Levothyroxine treatment and occurrence of fracture of the hip. Archives of Internal Medicine 2002 162 338-343.
104. Bauer DC, Ettinger B, Nevitt MC & Stone KL, for the Study of Osteoporotic Fractures. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Annals of Internal Medicine 2001 134 561-568.
105. Forfar JC, Feek CM, Miller HC & Toft AD. Atrial fibrillation and isolated suppression of the pituitary thyroid axis. Response to specific antithyroid therapy. International Journal of Cardiology 1981 1 43-48.
106. Faber J, Wiinberg N, Schifter S & Mehlsen J. Hemodynamic changes following treatment of subclinical and overt hyperthyroidism. European Journal of Endocrinalogy 2001 145 391-396.
107. Forfar JC, Miller H & Toft A. Occult thyrotoxicosis: a correctable cause of 'idiopathic' atrial fibrillation. American Journal of Cardiology 1979 44 9-12.
108. Chiacchieri M, Cecchi F, Arcangeli C, Dolara A, Zuppiroli A & Pieroni C. Occult thyrotoxicosis in patients with chronic and paroxysmal isolated atrial fibrillation. Clinical Cardiology 1984 7 413-416.
109. Faber J, Jensen IW, Petersen L, Nygaard B, Hegedus L & Siersbaek-Nielsen K. Normalization of serum thyrotropin by mean of radioiodine treatment in subclinical hyperthyroidism. Effect of bone loss in postmenopausal women. Clinical Endocrinology 1998 48 285-290.
110. Kong AW & Yeung SS. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin. Journal of Clinical Endocrinology and Metabolism 1996 81 1232-1236.
111. Rosen HN, Moses AC, Gundberg C, Kung VT, Seyedin SM, Chen T, Holick M & Greenspan SL. Therapy with parenteral pamidronate prevents thyroid hormone bone turnover in humans. Journal of Clinical Endocrinology and Metabolism 1993 77 664-669.
112. Rosen HN, Moses A, Garber J, Garber J, Ross DS, Lee SL, Ferguson L, Chen V, Lee K & Greenspan SL. Randomized trial of pamidronate in patients with thyroid cancer. Bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate. Journal of Clinical Endocrinology and Metabolism 1998 83 2324-2330.
113. Biondi B, Palmieri EA, Lombardi G & Fazio S. Effects of subclinical thyroid dysfunction on the heart. Annals of Internal Medicine 2002 137 904-914.
114. Thomas FB, Mazzaferri EL & Skillman TG. Apathetic thyrotoxicosis: a distinct clinical and laboratory entity. Annals of Internal Medicine 1970 72 679-685.
115. Sawin CT. Subclinical hyperthyroidism and atrial fibrillation. Thyroid 2002 12 501-503.